The Systems Biology of Drug Resistance in Cancer group, led by professor Sampsa Hautaniemi, focuses on understanding and finding effective means to overcome drug resistance in cancers. Our approach is to use systems biology, i.e., analyze molecular & clinical data from cancer patients with machine learning and mathematical methods, to identify efficient patient-specific therapeutic targets. Our work is cross-disciplinary and done in close collaboration with researchers from various disciplines, including clinicians, cell biologists and geneticians. The main objective of our research is to obtain hypotheses and predictions that can be tested in wet-lab or in clinical trials and thereby translate medical data into benefits in cancer patient care.
Read more
@HautaniemiLab

#SBLread twitter.com/NCIsysbio/stat…

📢attention genomics geeks 👩‍💻🧑‍🔬 an #openAccess text of our review on #mutation rate variation in #cancer genomes🧬i… twitter.com/i/web/status/1…

Tune into BME's Invited Speaker Series next week, on November 10th at 12:00pm EST. This month we have Dr. Doug Lauf… twitter.com/i/web/status/1…

Our agile workflow for #MassCytometry #DataAnalysis now out #openaccess in @OUPBioinf. Great work from @juliacsdtwitter.com/i/web/status/1…